Indication intelligence, analysis and sector perception

Caladrius Biosciences (CLBS) receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for treating CLI - BUY

April 10, 2018 8:50am

CLBS closed at $5.31 and is UP +$0.77 or +15.84%

The SAKIGAKE designation is part of Japan’s effort to accelerate the development and approval of regenerative medicines.

The strategy of SAKIGAKE includes a system for designating products for which prominent effectiveness (i.e. radical improvement compared to existing therapy) can be expected.

CLBS has received SAKIGAKE designation from the Japan Ministry of Health, Labor and Welfare (MHLW) for CLBS12 for the treatment of critical limb ischemia (CLI). CLBS12 is currently in a P2 trial in Japan for the treatment of no-option CLI, a severe obstruction of arterial blood flow to the extremities in patients that results in severe pain at rest and/or non-healing ulcers, which carry a risk of amputation.

The Pharmaceutical and Medical Devices Act (“PMDA”) enables an expedited path to conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy in P2 study and is similar to the Breakthrough Therapy Designation in the United States.

The CLBS12 P2 trial is a 35-patient prospective, randomized, controlled, multicenter study in no-option CLI patients in Japan. No-option CLI means that pharmacotherapy is unable to provide satisfactory treatment and that amputation of a limb or limbs is the next step in treatment for these patients. Patients randomized to treatment will be dosed with autologous G-CSF-mobilized peripheral blood-derived CD34 cells (CLBS12) through intramuscular injection, in addition to receiving standard of care pharmacotherapy. Patients randomized to the control arm will receive standard of care pharmacotherapy alone.

The primary endpoint is time to continuous CLI-free status.

BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

9 hours 43 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.